Qualit-E-SpeakPharma-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dotinurad

            Therapeutic Area: Rheumatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 25, 2020

            Details:

            Under this agreement, Eisai will proceed with the development of dotinurad in China.